Tag: Polatuzumab Vedotin
Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse...
Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...
The Story of World ADC Digital
As we plan ahead, for the upcoming digital World ADC Europe with much greater confidence, we were reflecting on what a year it has...
European Regulators Approve Polatuzumab Vedotin, Triggering Milestone Payment for Seattle Genetics
The European Commission's conditional marketing authorization of polatuzumab vedotin (Polivy®; Genentech/Roche) earlier this week triggered a milestone payment which Seattle Genetics will receive from...
Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma
Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of complete response (CR) among patients...
Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...
Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...
Polatuzumab Vedotin + Bendamustine and Rituxan Increased Complete Response Rates in...
Positive results from the randomized Phase II GO29365-study (NCT02257567) that compared polatuzumab vedotin (RG7596) in combination with bendamustine plus rituximab (Rituxan®; Genentech/Roche) against bendamustine plus...
Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...
Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...
Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...
Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...
ADC Market to Reach US$ 3 Billion by 2018
According to a report published by Research & Markets, one of the world's largest and most respected market research resource, the global market for Antibody-drug...
